Exclusive: Therini raises $36M, will target fibrin protein for Alzheimer’s and diabetic macular edema

Therini Bio has raised a $36 million Series A and will head to the clinic with an antibody that neutralizes fibrin, a blood clotting protein, that it hopes could have broad applications in tamping down inflammation.

Read more here.